ํด๋ ๋ถํ ๋กค
**ํด๋ ๋ถํ ๋กค(Clenbuterol)**์ ๊ฐ๋ ฅํ๊ณ ์ง์ ์๊ฐ์ด ๊ธด **๋ฒ ํ-2 ์๋๋ ๋ ๋ฆฐ ์์ฉ์ฒด ์์ฉ์ **๋ก, ์์ํ์์๋ ์ฃผ๋ก ๋ง์ ๊ธฐ๊ด์ง ํ์ฅ์ ๋ก ์ฌ์ฉ๋์ด **์ฌ๋ฐ์ฑ ๊ธฐ๋ ํ์(RAO)**(๊ณผ๊ฑฐ ๋ง์ฑ ํ์์ฑ ํ์งํ(COPD) ๋๋ '์ฒ๋ช ์ฆ'์ผ๋ก ๋ถ๋ฆผ)์ ๊ฐ์ ๊ธฐ๋ ํ์ ์งํ์ ๊ด๋ฆฌํ๋ ๋ฐ ์ฐ์ ๋๋ค. ํธํก๊ธฐ ์งํ ์ธ์๋ ์๋ง์ ๋์ฐ ๊ด๋ฆฌ๋ฅผ ๋๊ธฐ ์ํด **์๊ถ ์ด์์ (์๊ถ ์์ถ ์ต์ ์ )**๋ก ๊ฐํน ์ฌ์ฉ๋ฉ๋๋ค. ### ์ฃผ์ ์์ ํฌ์ธํธ: * **์์ฉ ๋๋ฌผ ์ฌ์ฉ ์๊ฒฉ ๊ธ์ง**: ํด๋ ๋ถํ ๋กค์ ๊ณ ์ฉ๋์์ ์ฒด์ฑ๋ถ ์ฌ๋ถ๋ฐฐ์ (๊ทผ์ก๋ ์ฆ๊ฐ ๋ฐ ์ง๋ฐฉ ๊ฐ์)๋ก ์์ฉํฉ๋๋ค. ์ค์ผ๋ ๊ณ ๊ธฐ๋ฅผ ์ญ์ทจํ ์ฌ๋์๊ฒ ์ฌ๊ฐํ **์๋ฅ ๋ ์ฑ(relay toxicity)**(์ฌํ ๋จ๋ฆผ, ๋น๋งฅ, ์ ์ ์ ๋ฐ)์ ์ผ์ผํค๋ ๊ฒ์ด ์ ์๋ ค์ ธ ์์ด, ์ ์ธ๊ณ์ ์ผ๋ก ์์ฉ ๋๋ฌผ์ ๋ํ ์ฌ์ฉ์ด ์๊ฒฉํ ๊ธ์ง๋์ด ์์ต๋๋ค. * **๋จ์ฉ ๊ฐ๋ฅ์ฑ**: ๋ํ ์คํ ๋ก์ด๋์ ์ ์ฌํ ํจ๊ณผ ๋๋ฌธ์ ์ธ๊ฐ์ ๋ณด๋๋น๋ฉ ๋ฐ ์ฒด์ค ๊ฐ๋ ๋ชฉ์ ์ผ๋ก ์์ฃผ ๋จ์ฉ๋ฉ๋๋ค. ์์์ฌ๋ ์ฝ๋ฌผ ์ ์ถ์ ๋ํด ๊ฐ๋ณํ ์ฃผ์ํด์ผ ํฉ๋๋ค. * **๋ด๋ถ๋น ๋ฐ ์ฌ์ฅ ์ํฅ**: ๋ง์๊ฒ ์ฅ๊ธฐ๊ฐ ํฌ์ฌ ์ ์ ์ฐ์ ์ด๋ ๋ฅ๋ ฅ ์ ํ, ์ฌ์ฅ ๋น๋, ์ฌ๊ทผ ๋ด ์ฝ๋ผ๊ฒ ์นจ์ค ๋ฐ ๋ฉด์ญ ๊ธฐ๋ฅ ๋ณํ๋ฅผ ์ด๋ํ ์ ์์ต๋๋ค.
์์ฉ ๊ธฐ์ : Clenbuterol selectively binds to and activates **beta-2 adrenergic receptors** on smooth muscle cells. ### Primary Pathway: **Beta-2 Receptor Activation** โ Stimulates **G_s proteins** โ Activates **Adenylyl Cyclase** โ Increases intracellular **cyclic AMP (cAMP)** โ Activates **Protein Kinase A (PKA)** โ Decreases intracellular calcium concentrations โ Results in **smooth muscle relaxation** (bronchial, vascular, and uterine). ### Secondary Mechanisms: * **Anti-inflammatory Effects**: Inhibits the release of pro-inflammatory cytokines (such as **Interleukin-1ฮฒ** and **Tumor Necrosis Factor-ฮฑ**) from pulmonary macrophages. * **Mucociliary Clearance**: Increases ciliary beat frequency in the respiratory tract, enhancing the clearance of excessive mucus associated with RAO.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Bronchodilator ยท Initially, 0.8 micrograms/kg (practically: 0.5 mL of the commercially available syrup/100 lb. BW) twice daily for 3 days; if no improvement increase to 1.6 micrograms/kg (practically: 1 mL of the commercially available syrup/100 lb. BW) twice daily for 3 days; if no improvement increase to 2.4 micrograms/kg (practically: 1.5 mL of the commercially available syrup/100 lb. BW) twice daily for 3 days; if no improvement increase to 3.2 micrograms/kg (practically: 2 mL of the commercially available syrup/100 lb. BW) twice daily for 3 days; if no improvement discontinue therapy. ยท PO ยท q12h ยท Recommended duration of therapy is 30 days; then withdraw therapy and reevaluate. ยท ARCI UCGFS Class 3 Drug
- Adjunctive treatment for dystocia emergencies ยท 300 micrograms per 500 kg mare IV slowly ยท IV ยท Single dose ยท Parenteral formulation not available commercially in the USA. Fast onset allows quick decision if uterine relaxation will correct the problem. May be used with sedatives/analgesics; xylazine or detomidine may potentiate uterine relaxant effects.
- Adjunctive treatment for dystocia emergencies ยท 10 mls of clenbuterol syrup orally as the mare walks in the door. ยท PO ยท Single dose ยท Author's hospital protocol upon arrival of a dystocia.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Food-producing animals (strictly banned by law)
- Horses suspected of having cardiovascular impairment
- Pregnant mares near full-term (unless used specifically for dystocia management)
์ด์๋ฐ์
- Muscle tremors
- Sweating
- Restlessness
- Urticaria
- Tachycardia
- Creatine kinase (CK) elevations
- Ataxia (rare)
- Abortion in pregnant animals
- Cardiac hypertrophy and collagen infiltration (with chronic use)
์ฝ๋ฌผ ์ํธ์์ฉ
- Inhalant Anesthetics (halothane, isoflurane, methoxyflurane) ยท May predispose the patient to ventricular arrhythmias, particularly with preexisting cardiac disease.
- Beta-Blockers (e.g., propranolol) ยท May antagonize clenbuterol's bronchodilating and tocolytic effects.
- Digoxin ยท May increase the risk of cardiac arrhythmias.
- Dinoprost (Prostaglandin F2alpha) ยท Clenbuterol may antagonize the ecbolic effects of dinoprost.
- Oxytocin ยท Clenbuterol may antagonize the uterine contracting effects of oxytocin.
- Other Sympathomimetic Amines (terbutaline, albuterol) ยท Concomitant administration may enhance the adverse cardiovascular and neurologic effects of clenbuterol.
- Tricyclic Antidepressants or MAOIs ยท May potentiate the vascular effects of clenbuterol.
๋ชจ๋ํฐ๋ง
- Clinical efficacy (improvement in respiratory rate, effort, and reduction of cough)
- Heart rate and rhythm (monitor for tachycardia or arrhythmias)
- Signs of muscle tremors, sweating, or restlessness
- Creatine kinase (CK) levels if myopathy is suspected
๊ณผ์ฉ๋
Overdoses can cause severe sympathomimetic toxicity (extreme tachycardia, arrhythmias, severe muscle tremors, hypertension followed by hypotension, and hypokalemia). **Treatment**: * **Decontamination**: Emptying the gut (gastric lavage/activated charcoal) may be appropriate depending on the dosage and timing of ingestion. * **Medical Management**: Provide supportive therapy. Administration of parenteral **beta-blockers** (e.g., propranolol, esmolol) may be considered to control heart rate, rhythm, and elevated blood pressure.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.